Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with locally advanced or metastatic kidney cancer.

Timeline

Start

2008-07

Primary completion

2011-10

Completion

2013-09

Drugs

Indications